Table 2 Univariate and multivariable proportional hazards model for relapse-free and overall survival for SUCCESS serum samples

Characteristic

Relapse-free survival

Overall survival

HR (95% CI)

P value

HR (95% CI)

P value

Menopausal status, post vs pre

1.323 (0.750–2.333)

0.335

2.872 (1.164–7.086)

0.022

Tumor size, T2-T4 vs T1

2.268 (1.187–4.332)

0.013

3.881 (1.343–11.218)

0.012

Lymph node involvement, N1-3 vs N0

1.645 (0.861–3.142)

0.132

3.012 (1.045–8.683)

0.041

Estrogen receptor (ER) status, ER- vs ER+

1.316 (0.999–1.734)

0.051

1.333 (0.918–1.934)

0.131

Progesterone receptor (PR) status, PR- vs PR+

1.180 (0.897–1.554)

0.237

1.219 (0.839–1.772)

0.298

HER2 status, HER2+ vs HER2-

1.907 (0.858–4.241)

0.113

1.789 (0.618–5.178)

0.283

Grading, G3 vs G1/2

1.079 (0.623–1.868)

0.786

1.129 (0.535–2.384)

0.75

CTCs before chemo, CTC+ vs CTC-

3.666 (2.110–6.368)

<0.0001

5.681 (2.686–12.014)

<0.0001

CTCs after chemo, CTC+ vs CTC-

1.401 (0.757–2.592)

0.283

1.467 (0.646–3.331)

0.36

EFC#93 before chemo, EFC#93+ vs EFC#93-

4.912 (2.613–9.233)

<0.0001

7.689 (3.518–16.804)

<0.0001

EFC#93 after chemo, EFC#93+ vs EFC#93-

1.913 (0.927–3.949)

0.079

1.807 (0.673–4.853)

0.24

Relapse-free survival

Overall survival

HR (95% CI)

P value

HR (95% CI)

P value

Menopausal status

1.294 (0.728–2.302)

0.379

2.688 (1.070–6.750)

0.035

Tumor size

1.763 (0.914–3.401)

0.091

2.945 (1.009–8.597)

0.048

Lymph node involvement

1.442 (0.750–2.775)

0.273

2.242 (0.765–6.566)

0.141

CTCs before chemo

2.847 (1.613–5.024)

0.0003

3.623 (1.681–7.812)

0.001

EFC#93 before chemo

3.782 (1.965–7.281)

<0.0001

5.973 (2.634–13.542)

<0.0001